Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 174 participants.

Also called NCT06721442

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 174 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06721442
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06721442. Randomized; no masking; primary purpose prevention. Start 2023-01-10 (actual); primary completion 2023-12-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Dapagliflozin on Electrocardiographic Parameters in Type 2 Diabetes Patients: DAPA - ECG Study
Acronym
DAPA-ECG
Condition
Arrhythmias, Cardiac
Condition
Diabetes Mellitus
Intervention (Drug)
Dapagliflozin (DAPA)
Lead sponsor
Beneficência Portuguesa de São Paulo (class: other)
Collaborator
Instituto Dante Pazzanese de Cardiologia (class: other)

Record details

Record id
cardio:ct-nct06721442
Content hash
9486ab2c9c7db68ef9fe582732e2e222333483bbf754e34fee8fbc842f60c359